EGFR-mutant lung adenocarcinoma in a patient with Li-Fraumeni syndrome.

EGFR-mutant lung adenocarcinoma in a patient with Li-Fraumeni syndrome. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

EGFR-mutant lung adenocarcinoma in a patient with Li-Fraumeni syndrome. Abstract Text:

Lynne T Bemis,William A Robinson,Robert McFarlane,Elizabeth Buyers,Karen Kelly,Marileila Varella-Garcia,John D Mitchell,Wilbur A Franklin,

EGFR-mutant lung adenocarcinoma in a patient with Li-Fraumeni syndrome. Publishing Authors By Initials

LT Bemis,WA Robinson,R McFarlane,E Buyers,K Kelly,M Varella-Garcia,JD Mitchell,WA Franklin,

For similar enzymes and coenzymes: enzymes: transferases: phosphotransferases: phosphotransferases (alcohol group acceptor): protein kinases: protein-tyrosine kinases: receptor protein-tyrosine kinases: receptor, epidermal growth factor research abstracts see: enzymes and coenzymes: enzymes: transferases: phosphotransferases: phosphotransferases (alcohol group acceptor): protein kinases: protein-tyrosine kinases: receptor protein-tyrosine kinases: receptor, epidermal growth factor research

PUBMED ID PMID:

MEDLINE DATE:

EGFR-mutant lung adenocarcinoma in a patient with Li-Fraumeni syndrome. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: The lancet oncology

VOLUME: 8

Page Numbers: 559-60

Journal Abbreviation: Lancet Oncol.

ISSN: 1470-2045

DAY: 3

MONTH: Jun

YEAR: 2007

EGFR-mutant lung adenocarcinoma in a patient with Li-Fraumeni syndrome. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 100957246

EGFR-mutant lung adenocarcinoma in a patient with Li-Fraumeni syndrome. Keywords Mesh Terms:

KEYWORDS: Receptor, Epidermal Growth Factor

MESH TERMS: genetics

Chemical & Substance for Abstract: EGFR-mutant lung adenocarcinoma in a patient with Li-Fraumeni syndrome. Information

Substance Name: Receptor, Epidermal Growth Factor

Registry Number: EC 2.7.1.112

Grant and Affiliation Information for EGFR-mutant lung adenocarcinoma in a patient with Li-Fraumeni syndrome.

AFFILIATION: Department of Medicine, University of Colorado at Denver and Health Sciences Center, Aurora, CO, USA.

Country: England

AGENCY: United States NCI

GRANT: U01-CA85070

ACRONYM: CA

MEDLINETA: Lancet Oncol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

EGFR-mutant lung adenocarcinoma in a patient with Li-Fraumeni syndrome Related Publications

• 'Crook' pipettes: embryonic emigrations from agriculture to reproductive biomedicine.
• 145.
• Appropriateness of Exercise Testing in Asymptomatic Men and Women: Improved Clinical Outcomes?: 73: 2:10 PM-2:40 PM.
• Bax affects production of reactive oxygen by the mitochondria of non-apoptotic neurons.
• Breeding colony refinement through phenotypic and genotypic characterization of the SPRD-Pkdr1/Rrrc rat model of polycystic kidney disease.
• Cardiologists' Perception of Secondary Prevention and Cardiac Rehabilitation Referral Patterns: Influence of Personal Lifestyle Practices: 1724: Board #12 May 31 9:00 AM - 10:30 AM.
• Cardiorespiratory fitness in older adults referred for diagnostic exercise testing: modulating variables: 2385: board #64 june 1 2:00 PM -3:30 PM.
• Characterization of cecal gene expression in a differentially susceptible mouse model of bacterial-induced inflammatory bowel disease.
• Cognitive behavioral treatment for young children with obsessive-compulsive disorder.
• Comparative phylogeography and genetic structure of Vanuatu birds: control region variation in a rail, a dove, and a passerine.
• Conventional Screening Guidelines: 127: 3:20 PM-3:45 PM.
• Dietary behaviors and knowledge among urban pre-adolescents: 1581: board #71 may 30 3:30 PM - 5:00 PM.
• Dose-response relationships between vigorous exercise and prevalence of diabetic, hypertensive, and hypercholesterolemia medication use: 709: may 31 1:30 PM 1:45 PM.
• EGFR-mutant lung adenocarcinoma in a patient with Li-Fraumeni syndrome.
• Effect of metabolic inhibitors on ATP and citrate content in PC3 prostate cancer cells.
• Energy Expenditure, Epicardial Adipose Tissue and Cardiorespiratory Fitness in Morbidly Obese Adults: 2154: Board #67 June 1 8:00 AM - 9:30 AM.
• Function and Mortality in Coronary Patients: Cardioprotective Mechanisms: 207: 1:45 PM-2:15 PM.
• Influence of a High-Intensity Resistance Training Program on Muscular Strength in Coronary Patients: 1731: Board #19 May 31 9:00 AM 10:30 AM.
• Introduction and Overview: 70: 1:00 PM-1:10 PM.
• Lifestyle Activity in Patients Engaged in Phase 3 Cardiac Rehabilitation: Scheduled Versus Non-Scheduled Exercise Days: 1733: Board #21 May 31 9:00 AM 10:30 AM.
• Murine hepatoma (Hepa1c1c7) cells: a responsive in vitro system for chemoprotective enzyme induction by organoselenium compounds.
• Prognostic factors of long-term disability in a workers' compensation system.
• Reactive oxygen intermediates and signaling through kinase pathways.
• Reactive oxygen species-induced activation of the MAP kinase signaling pathways.
• Resistance Training-Induced Attenuation of the Hemodynamic Responses to Standardized Lifting in Coronary Patients: 657: May 31 9:45 AM 10:00 AM.
• Supine and prone stress myocardial perfusion imaging in women evaluated for suspected coronary artery disease: 2390: board #69 june 1 2:00 PM -3:30 PM.
• The antimutagenicity of 2-substituted selenazolidine-4-(R)-carboxylic acids.
• Traumatic and socially stressful life events among persons with social anxiety disorder.
• Tumor cell metabolism: the marriage of molecular genetics and proteomics with cellular intermediary metabolism; proceed with caution!
• Use of VE/VCO2 slope Corrected for Peak VO2 as a Predictor of Post-Surgical Complications in Morbidly Obese Patients: 686: May 31 8:30 AM 8:45 AM.